RegeneRx接收兩個心臟相關的專利申請津貼的通知
商業 WirePress發布:RegeneRx生物製藥公司 - 週四,11月17日,20111:35 PM EST
電子郵件
打印
公司:
Regenerx生物製藥公司
專題報導
符號升跌
RGRX.OB0.16-0.02
,馬里蘭州羅克維爾 - (BUSINESS WIRE) - RegeneRx生物製藥公司(場外交易公告牌:RGRX)(“公司”或“RegeneRx”)今天宣布,該公司已通 知兩個心臟相關的專利將允許在澳大利亞和墨西哥。
澳大利亞專利和將到期,2026年7月因心臟衰竭的治療或預防。
墨西哥的專利是用於治療或預防心肌血流增加造成的損害,通常稱為再灌注損傷。它會,2026年1月屆滿。
RegeneRx已經在許多其他國家的同類專利申請中,包括在美國,亞洲和歐洲。
RegeneRx Receives Notice of Allowance on Two Cardiac-Related Patent Applications
Business WirePress Release: RegeneRx Biopharmaceuticals, Inc. – Thu, Nov 17, 2011 1:35 PM EST
Email
Print
Companies:
Regenerx Biopharmaceuticals Inc.
RELATED QUOTES
Symbol Price Change
RGRX.OB 0.16 -0.02
ROCKVILLE, Md.--(BUSINESS WIRE)-- RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) announced today that the Company has been notified that two cardiac-related patents will be allowed in Australia and Mexico.
The Australian patent is for the treatment or prevention of damage due to heart failure and will expire in July, 2026.
The Mexican patent is for the treatment or prevention of damage caused by increased blood flow in the myocardium, commonly called reperfusion injury. It will expire in January, 2026.
RegeneRx has similar patents pending in numerous other countries, including in the U.S., Asia and Europe.
專題報導
符號升跌
UVFT.OB 0.0440 -0.0040
森特維爾,馬薩諸塞州,2011年11月10日/新華美通/ - 紫外線感技術公司(OTCBB:UVFT)(“本公司”)欣然宣布,它已擴大其國際分銷代表在阿曼加入,和斯里蘭卡, 斯里蘭卡,同時繼續擴大該公司在印度的分銷商,Ormed系統,整個印度在醫療設備銷售和服務的領導者,以及世界其他 地區的關係。該公司將繼續努力,在中國,中東,並已開始在南美洲的代表舉行會談。
“對我們產品的市場潛力外,這個國家是沒有什麼非凡的,說:”傑克儂,紫外線感科技總裁。在許多地方,“在世界其他地 方的室內空氣污染可以比我們環保局將有資格為不健康的差幾百倍。已發現室內空氣污染有直接鏈接到各種健康問題,包括, 但不僅限於呼吸系統問題,如哮喘,過敏,肺炎,睡眠問題,能耗低,糖尿病,甚至心血管問題。“
“我們認為,許多其他國家更遠的室內空氣質量的重要性方面的學習曲線,印度和中國是兩個最大的,我們計劃上的支持和擴 大我們的國際努力,同時發動國內的一些巨大的舉措。為此,公司已開始評估其選項與尊重,以提高其生產能力,並認為,2 012年銷售其產品可以多次2011年,儂先生說。“
關於本公司的業務,收購,財務報告和協議的詳細是提交作為本公司的持續公眾披露一部分作為一個根據的證券交易所法“1 934年報告的證券和交易委員會的(”證交會“)的EDGAR數據庫提交發行人。欲了解更多信息,請訪問:www.uvflutech.com。
UV Flu Technologies Expands Its International Footprint
RELATED QUOTES
Symbol Price Change
UVFT.OB 0.0440 -0.0040
CENTERVILLE, Mass. , Nov. 10, 2011 /PRNewswire/ -- UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce it has expanded its International Distribution by adding representation in Oman , and Sri Lanka , while continuing to expand its relationship with the Company's Distributor in India , Ormed Systems, a leader in medical equipment sales and services throughout India , as well as other parts of the world. The Company continues efforts in China , the Mideast, and has begun talks with representation in South America .
"The market potential for our products outside of this Country is nothing short of extraordinary," said Jack Lennon , President of UV Flu Technologies. "Indoor air pollution in other parts of the world in many locations can be hundreds of times worse than what our EPA would qualify as unhealthy. Indoor air pollution has been found to have direct links to a variety of health problems, including, but not limited to, respiratory issues such as asthma, allergies, and pneumonia, sleep problems, low energy, diabetes, and even cardiovascular problems."
"We think many other countries are farther down the learning curve with respect to the importance of indoor air quality, and India and China are two of the biggest. We plan on supporting and expanding our international efforts, while launching some huge initiatives domestically. To this end, the Company has begun evaluating its options with respect to increasing its production capabilities, and feels that the sales of its products in 2012 could be many times those of 2011," said Mr. Lennon.
Further details regarding the Company's business, acquisitions, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit: www.uvflutech.com.